Infectious Diseases and Therapy (Jul 2020)

HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir

  • Alex E. Rock,
  • Patricia L. DeMarais,
  • Pamala T. Vergara-Rodriguez,
  • Blake E. Max

DOI
https://doi.org/10.1007/s40121-020-00307-4
Journal volume & issue
Vol. 9, no. 3
pp. 691 – 696

Abstract

Read online

Abstract A potential drug-drug interaction exists between divalent and trivalent cations (Ca2+, Fe3+, Mg2+, Al3+, Zn2+) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements. This case represents a potential significant drug interaction between a commonly prescribed antiretroviral drug class and readily available over-the-counter divalent cation products.

Keywords